Tech Support

TECHNICAL SUPPORT
+1.800.674.3430

This line is for technical support.
For General Enquiries please click General Contact

SYMPOSIUM: Advanced Strategies for Translational Oncology Research

Thursday October 3, 2019 - Hilton Torrey Pines, San Diego CA

Crown Bioscience invites you to attend our San Diego symposium focused on Advanced Strategies for Translational Oncology Research. Join the discussion on new targets, technologies, and enhanced models for developing the next generation of oncology and immuno-oncology agents.

NEW WHITE PAPER! HUB Organoid Technology: Advantages in 3D In Vitro Modeling

Review the breakthrough discoveries leading to the development of HUB Organoids. Explore the key features of these 3D in vitro models including organ morphology recapitulation, stability, genomic superiority, and long-term culture, as well as their main utilities in research and development.

WEBINAR: How to Detect, Characterize, and Evaluate CAR-T Cell Therapies

Thursday October 10, 2019 - 4am/10am/5pm EST

Presented by Dr Rajendra Kumari this webinar will explore how to overcome translational challenges in CAR-T cell therapy development. She'll discuss the different preclinical models available for CAR-T and cell therapy efficacy and safety assessment including PDX, as well as a novel rare cell analysis platform for sensitive CAR-T detection.

Review our 9 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Posters

Preview our poster topics now covering a wide variety of preclinical oncology and immuno-oncology platforms including tumor organoids for drug discovery and I/O drug development, orthotopic syngeneic models, and immunoprofiling data.

ON DEMAND WEBINAR: Preclinical Obesity Research: Best Practice in Model Selection and Study Design

Presented by Dr Fred Beasley this webinar explores how to select the most appropriate models for your preclinical obesity studies, including polygenic vs monogenic models and recommendations based on drug modes of action. We also review best practice in obesity study design to maximize data outcomes.

ON DEMAND WEBINAR: Demonstrating Clinical Relevance in 3D In Vitro Modeling with HUB Organoids

Presented by Dr Sylvia Boj, Hubrecht Organoid Technology this webinar reviews the development and application of HUB Organoids. Explore the many advantages of HUB Organoids within 3D in vitro modeling, including direct clinical relevance and immuno-oncology applications.

NEW WHITE PAPER: How to Assess Immunotherapy Toxicity using NHPs

Learn more about NHPs as a valuable early-stage preclinical platform for non-GLP exploratory toxicology studies. Explore the robust data these studies generate in a rapid, flexible, and cost-effective manner to assess immunotherapy safety and de-risk future clinical trials.

WHITE PAPER: Optimizing Translational IBD Capabilities How to Select the Right Preclinical Model

Explore the key features of commonly used preclinical IBD models, including model development and example treatment studies. Learn how to choose the most appropriate model for your drug development program, based on drug target and mechanism of action alongside model disease pathogenesis and clinical relevance.

Download our ADA 2019 Posters

We presented posters on our unique translational NASH model at the ADA Scientific Sessions this year. Download our latest data on NASH induction in the dysmetabolic MS-NASH mouse (formerly FATZO), and accelerated disease induction resulting in a model featuring both severe fibrosis and dysmetabolism.

CVMD

Models of Obesity

obesity-img.jpg

CrownBio’s preclinical Translational Technology Platforms provide spontaneous & diet-induced obesity (DIO) models, to support the transition of new agents into the clinic.

Learn More

Oncology

Oncology Databases

databases-img.jpg

Our unique databases provide a curated source of well-characterized models available to use for drug discovery including PDX models, cell lines, and syngeneic models.

Learn More

CVMD

Diabetes Models

oncoexpress-img.jpg

Models of both Type 1 and Type 2 diabetes, including conventional, as well as unique, highly translatable models for in vivo efficacy studies of antidiabetic agents.

Learn More

Latest from our Blog

September 19, 2019

Key Discoveries in the Development of Modern HUB Organoids

Learn about the key research discoveries leading to the development of modern HUB Organoids.

Read More

September 19, 2019

Key Discoveries in the Development of Modern HUB Organoids

Learn about the key research discoveries leading to the development of modern HUB Organoids.

Read More

September 17, 2019

Targeting Tumor-Associated Antigens and Tumor-Specific Antigens

Learn more about targeting human tumor-associated antigens (TAAs) or tumor-specific antigens...

Read More

September 13, 2019

HUB Tumor Organoids: Top 15 Questions

Review the key questions on HUB tumor organoids from our recent webinar, answered by Dr Sylvia...

Read More

September 11, 2019

HUB Organoids: Top 9 Technical Questions

Review the top 9 technical questions on HUB organoid development from our recent webinar,...

Read More

September 10, 2019

How to Assess Immunotherapy Toxicity with NHP Models

How to Assess Immunotherapy Toxicity with NHP Models

Explore non-GLP exploratory toxicology NHP...

Read More

Upcoming Events


September 16 - 19, 2019

Discovery on Target

Boston, MA


September 17 - 20, 2019

Storm RNA Epigenetics Conference

Cambridge, UK


September 23 - 25, 2019

7th Helmholtz Diabetes Conference

Munich, Germany


September 25, 2019

US West Coast Immuno-Oncology Xchange

San Francisco, CA


September 25 - 28, 2019

Fifth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Translating Science Into Survival

Paris, France